Deep brain stimulation in early Parkinson's disease: Enrollment experience from a pilot trial

Parkinsonism and Related Disorders

Volumn 18, Issue 3, 2012, Pages 268-273

  Charles, P D ^a   Dolhun, R M ^a   Gill, C E ^b   Davis, T L ^a   Bliton, M J ^a   Tramontana, M G ^a   Salomon, R M ^a   Wang, L ^a   Hedera, P ^a   Phibbs, F T ^a   Neimat, J S ^a   Konrad, P E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Deep brain stimulation; Parkinson's disease; Subthalamic nucleus

Indexed keywords

LEVODOPA;

ADULT; AGED; APHASIA; APNEA; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DROWSINESS; DYSPHAGIA; ERYTHEMA; FACE EDEMA; FEMALE; HALLUCINATION; HEADACHE; HEMATOMA; HUMAN; INSOMNIA; MALE; MYALGIA; NAUSEA; NECK PAIN; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; SKIN TINGLING; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; URINE RETENTION; VOMITING; WEAKNESS; WOUND HEALING;

AGED; DEEP BRAIN STIMULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SELECTION; PILOT PROJECTS; SINGLE-BLIND METHOD;

EID: 84857440499     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.11.001     Document Type: Article

References (33)

1. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004, 55:41-60.
2. FDA Premarket approval for Medtronic Activa tremor control system 1997, [updated 2011 Jul 29; cited 2011 Aug 11]; Available from:. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm%3Fid%3D8621.
3. Schulz D. Medtronic Activa Parkinson's control therapy 2002, [cited 2011 Aug 11]; Premarket approval letter. Available from:, Food and Drug Administration, Rockville, MD. http://www.accessdata.fda.gov/cdrh_docs/pdf/p960009S7a.pdf.
4. Weaver F.M., Follett K., Stern M., Hur K., Harris C., Marks W.J., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009, 301:63-73.
5. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355:896-908.
6. Benabid A.L., Chabardes S., Mitrofanis J., Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009, 8:67-81.
7. Lozano A.M., Mahant N. Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences. Parkinsonism Relat Disord 2004, 10(Suppl. 1):S49-S57.
8. Charles P.D., Padaliya B.B., Newman W.J., Gill C.E., Covington C.D., Fang J.Y., et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 2004, 10:475-479.
9. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003, 349:1925-1934.
10. Shichi T., Okiyama R., Yokochi F., Taniguchi M., Takahashi H., Hamada I. Unilateral subthalamic stimulation for early-stage Parkinson's disease. No To Shinkei 2005, 57:495-498.
11. Mesnage V., Houeto J.L., Welter M.L., Agid Y., Pidoux B., Dormont D., et al. Parkinson's disease: neurosurgery at an earlier stage?. J Neurol Neurosurg Psychiatry 2002, 73:778-779.
12. Schupbach W.M., Maltete D., Houeto J.L., du Montcel S.T., Mallet L., Welter M.L., et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007, 68:267-271.
13. Schapira A.H., Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004, 291:358-364.
14. Olanow C.W., Stern M.B., Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009, 2009(72):S1-136.
15. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998, 44:S175-S188.
16. Piallat B., Benazzouz A., Benabid A.L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996, 8:1408-1414.
17. Nakao N., Nakai E., Nakai K., Itakura T. Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol 1999, 45:640-651.
18. Maesawa S., Kaneoke Y., Kajita Y., Usui N., Misawa N., Nakayama A., et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg 2004, 100:679-687.
19. Temel Y., Visser-Vandewalle V., Kaplan S., Kozan R., Daemen M.A., Blokland A., et al. Protection of nigral cell death by bilateral subthalamic nucleus stimulation. Brain Res 2006, 1120:100-105.
20. Visser-Vandewalle V., van der Linden C., Temel Y., Celik H., Ackermans L., Spincemaille G., et al. Long-term effects of bilateral subthalamic nucleus stimulation in advanced Parkinson disease: a four year follow-up study. Parkinsonism Relat Disord 2005, 11:157-165.
21. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-183.
22. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278.
23. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
24. Charles P.D., Gill C.E., Davis T.L., Konrad P.E., Benabid A.L. Is deep brain stimulation neuroprotective if applied early in the course of PD?. Nat Clin Pract Neurol 2008, 4:424-426.
25. Lang A.E., Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002, 17(Suppl. 3):S94-101.
26. Hauser R.A., Holford N.H.G. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002, 5(17):961-968.
27. Tabbal S.D., Revilla F.J., Mink J.W., Schneider-Gibson P., Wernie A.R., de Erausquin G.A., et al. Safety and efficacy of subthalamic nucleus deep brain stimulation performed with limited intraopeerative mapping for treatment of Parkinson's disease. Neurosurgery 2007, 61(Suppl 3):119-127.
28. Lyons K.E., Wilkinson S.B., Overman J., Pahwa R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004, 63:612-616.
29. Pahwa R., Wilkinson S.B., Overman J., Lyons K.E. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg 2003, 99:71-77.
30. Wider C., Pollo C., Bloch J., Burkhard P.R., Vingerhoets F.J. Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord 2008, 14:114-119.
31. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
32. Ogasahara S., Nishikawa Y., Takahashi M., Wada K., Nakamura Y., Yorifuji S., et al. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease. J Neurol Sci 1984, 66:151-163.
33. Barbato L., Stocchi F., Monge A., Vacca L., Ruggieri S., Nordera G., et al. The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol 1997, 20:394-401.